Norwegian study demonstrates targeted coxibs may prevent oral cancer

November 21, 2002

Frankfurt, Germany: Norwegian researchers are planning the world's first phase III randomised trial to prevent head and neck cancer.

They will use COX-2 inhibitors (coxibs) - a particular type of non-steroidal anti-inflammatory group of drugs (NSAID) - better known as a treatment for conditions such as arthritis. These drugs block the action of COX-2 (cyclooxygenase-2), an enzyme found mainly in inflammatory and immune cells and now suspected of playing a role in cell growth and genetic instability.

Dr Jon Sudbø, Consultant at the Department of Oncology at the Norwegian Radium Hospital in Oslo, revealed plans for the trial at a news briefing today (Thursday 21 November) at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics[1], in Frankfurt, Germany.

His team at the Norwegian Radium Hospital and colleagues from the University of Oslo Department of Oral Biology, have carried out a study to compare levels of COX-2 expression in three groups of people - 30 with healthy mucous membranes in their mouths, 22 with dysplastic (premalignant) lesions and 29 with oral cancer. The objective was to see whether the levels of COX-2 were linked to aneuploidy (aberrant numbers of chromosomes) in the DNA, indicating a genetic risk marker for cancer. The results are being presented for the first time at the Frankfurt conference.

"We found that COX-2 expression was up regulated from healthy to premalignant lesions and to cancerous oral mucosa," said Dr Sudbø. "There was COX-2 expression in one healthy patient (3%) but all the healthy group had normal DNA. Among those with cancer 26 (88%) had COX-2 expression and 25 (94%) had aneuploidy. But, most notably, we found that of the 22 patients with dysplastic lesions, COX-2 was exclusively expressed in a subgroup of nine (41%) who we identified at high risk of cancer by the aberrant DNA in their lesion. Of these nine patients, we followed seven for at least five years and six of those (85%) went on to develop oral cancer.

"This is the first time that it's been demonstrated that COX-2 is up-regulated in high-risk oral lesions. So, this is also the first demonstration that it may be possible to use targeted coxibs to prevent oral cancer."

Dr Sudbo said that oral cancer was ideal for investigating chemoprevention because it was normally preceded by readily detectable lesions that can be identified and monitored without very sophisticated equipment or procedures.

"Typically, there is a lead-in time of five to 10 years between the occurrence of dysplasia and the development of cancer, so there is ample time to intervene with preventive treatment.

"Quite frankly we regard both the study and the forthcoming trial as a significant development, whatever the results turn out to be. With few and notable exceptions, treating manifest cancers is not an optimal approach to this group of diseases. Treating precursor lesions is a much more attractive approach, mainly because the complexity of the disease in early stages is not as pronounced as in more advanced stages."

He said that most approaches to chemoprevention have failed and this was probably because reliable identification of high-risk individuals had not been possible. The Norwegian Cancer Society had therefore up to now had a "wait and see" approach to chemoprevention.

"Now we have identified risk markers this has changed, at least for oral cancer. The Norwegian Cancer Society is funding the trial with the Norwegian Radium Hospital as the primary investigating site. Our randomised trial, using celecoxib, will involve patients with aneuploid white patches in their oral mucosa. Our target is to recruit 350 patients and we expect the trial to last five years and to follow our patients for 10 years."

Dr Sudbø said that head and neck cancers shared common risk factors with lung cancers. "An interesting spin-off will be to see whether the use of coxibs for preventing oral cancer will also influence the incidence rates of lung cancer. Selective coxibs have already been shown to influence the role of colon polyps," he added.
-end-
Notes:

[1] EORTC [European Organisation for Research and Treatment of Cancer; NCI [National Cancer Institute]; AACR [American Association for Cancer Research].

  • In the year 2000 there were 266,672 cases of oral cancer worldwide (169,524 men and 97,148 women) and a total of 127,902 deaths (80,839 men and 47,063 women).

  • In Europe there were 57,078 cases (43,286 men and 13,792 women) and 22,148 deaths (17,349 men and 4,799 women).

  • In the USA there were 18,821 cases (10,998 men and 7,823 women) and 4,383 deaths (2,765 men and 1,618 women).

    Source: Globocan 2000 Estimates (IARC).
    More detailed figures: http://www-dep.iarc.fr/globocan/globocan.html

    The main risk factors for oral cancer are tobacco and alcohol. Nine out of 10 of those developing the disease are smokers or chew tobacco. Smokers are six times more likely than non-smokers to develop oral cancer. Three-quarters of those developing oral cancer consume alcohol frequently. Tobacco and alcohol act synergistically, raising the risk even higher.

    Further information:
    Margaret Willson (media information officer)
    Tel: 44-153-677-2181
    Fax: 44-153-677-2191
    Mobile: 44-797-385-3347
    Email: m.willson@mwcommunications.org.uk

    From: 16:00hrs CET Monday 18 November to 17:00hrs CET Friday 22 November
    EORTC-NCI-AACR symposium press office:
    Tel: 49-697-5757-3294
    Fax: 49-697-5757-3451

    European Organisation for Research and Treatment of Cancer

    Related Cancer Articles from Brightsurf:

    New blood cancer treatment works by selectively interfering with cancer cell signalling
    University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

    UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
    A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

    Breast cancer treatment costs highest among young women with metastic cancer
    In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

    Cancer mortality continues steady decline, driven by progress against lung cancer
    The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

    Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
    Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

    Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
    The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

    Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
    Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

    More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
    An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

    New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
    Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

    American Cancer Society outlines blueprint for cancer control in the 21st century
    The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

    Read More: Cancer News and Cancer Current Events
  • Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.